Contributions to Personalized and Precision Medicine & Genomic Research: Larry H. Bernstein, MD, FCAP
Curator: Aviva Lev-Ari, PhD, RN
Open Access Online Scientific Journal
Launched on 4/30/2012
http://pharmaceuticalintelligence.com
Site Statistics on 2/18/2016
|
Date |
Views to Date |
# of articles |
NIH Clicks |
Nature Clicks |
|
6/24/2013 |
199,857 |
1,034 |
1,275 |
661 |
| 7/29/2013 | 217,356 | 1,138 | 1,389 | 705 |
| 12/11/2013 | 293,694 | 1,464 | 1,693 | 828 |
| 10/17/2015 | 765,762 | 3,444 | 2,726 | 1,683 |
| 02/18/2016 | 886,454 | 4,162 | 2,911 | 1,813 |
On 2/18/2016, Aviva Lev-Ari, PhD, RN had curated 2,333 articles, since Journal’s Launch.
- The list of titles is on 118 pages on http://pharmaceuticalintelligence.com
- Links to each article to be found at
http://pharmaceuticalintelligence.com/?s=Aviva+Lev-Ari%2C+PhD%2C+RN
- Frontiers in Cardiology – 653 articles
http://pharmaceuticalintelligence.com/?s=Frontiers+in+Cardiology
These articles have been viewed, since the first article was published on 4/30/2012, by
+886,454 e-Readers
| Author and Curator | e-Readers since
4/30/2012 |
Journal Articles on
2/18/2016 |
|---|---|---|
Aviva Lev-Ari, PhD, RN |
248,163 | 2,333 |
Larry H Bernstein, MD, FCAP |
155,253
|
1,183 |
Top Authors for all days ending 2016-02-18 (Summarized)
site stats 2-18-16
|
Top Authors for all days ending 2016-02-18 (Summarized) |
||||
|
Author |
Views |
|||
| Aviva Lev-Ari,
PhD, RN |
248,163 | |||
| larryhbern, MD, FCAP | 155,253 | |||
| tildabarliya | 37,900 | |||
| sjwilliamspa | 26,687 | |||
| Dror Nir | 20,295 | |||
| Dr. Sudipta Saha | 17,558 | |||
| ritusaxena | 13,846 | |||
| Demet Sag, Ph.D., CRA, GCP | 9,543 | |||
| aviralvatsa | 7,528 | |||
| zraviv06 | 6,048 | |||
| zs22 | 3,316 | |||
| anamikasarkar | 3,090 | |||
| pkandala | 2,056 | |||
| Alan F. Kaul, PharmD., MS, MBA, FCCP | 1,854 | |||
| Aashir Awan, Phd | 1,551 | |||
| megbaker58 | 1,336 | |||
| jdpmd | 1,053 | |||
| danutdaagmailcom | 564 | |||
| Irina Robu | 543 | |||
| howarddonohue | 504 | |||
| Ed Kislauskis | 487 | |||
| S. Chakrabarti, Ph.D. | 476 | |||
| apreconasia | 276 | |||
| evelinacohn | 240 | |||
| anayou1 | 221 | |||
| jukkakarjalainen | 216 | |||
| Dr.Sreedhar Tirunagari | 143 | |||
| stuartlpbi | 47 | |||
| gerag2015 | 44 | |||
| Rosalind Codrington, PhD | 20 | |||
Contributions to Personalized Medicine
Larry H Bernstein, MD, FCAP
Dr. Bernstein had advanced the Personalized Medicine Paradigm in a pursuit of over 40 years of a career in Medicine.
In his own words:
A Perspective on Personalized Medicine
http://pharmaceuticalintelligence.com/2016/02/22/a-perspective-on-personalized-medicine/
My Life in Medicine: Larry H. Bernstein, M.D.
www.linkedin.com/pub/larry-h-bernstein/a/599/50
I retired from a five year position as Chief of the Division of Clinical Pathology (Laboratory Medicine) at New York Methodist Hospital-Weill Cornell Affiliate, Park Slope, Brooklyn in 2008 followed by an interim consultancy at Norwalk Hospital in 2010. I then became engaged with a medical informatics project called “Second Opinion” with Gil David and Ronald Coifman, Emeritus Professor and Chairman of the Department of Mathematics in the Program in Applied Mathematics at Yale. I went to Prof. Coifman with a large database of 30,000 hemograms that are the most commonly ordered test in medicine because of the elucidation of red cell, white cell and platelet populations in the blood. The problem boiled down to a level of noise that exists in such data, and developing a primary evidence-based classification that technology did not support until the first decade of the 21stcentury. READ MORE
http://pharmaceuticalintelligence.com/contributors-biographies/members-of-the-board/larry-bernstein/
In my own words:
Curator: Aviva Lev-Ari, PhD, RN
Of all the readings and reviews I completed to date, my appreciation got bonded to two Science and Medicine writers:
- a Young Surgeon, Atul Gawande, MD, MPH
and
- a Retired Pathologist, Pathophysiologist, Histologist, Bacteriologist, Chemical Geneticist, BioChemist, Enzymologist, Molecular Biologist, Mathematical Statistician and more, Larry H. Bernstein, MD, FCAP
I am inviting the e-Readers to join me on a language immersion during a LITERARY TOUR in Science, Medicine and HealthCare Policy.
- Dr. Bernstein has expressed his views on Personalized Medicine in a series of articles on Predicted Cost of Care and the Affordable Care Act, Impact of 2013 HealthCare Reform in the US & Patient Protection and Affordable Care Act
- His views of advocacy for Personalized Medicine are expressed in EIGHT Books and another two in the Printing Process for 2016 publication, as follows:
2013 e-Book on Amazon.com
- Perspectives on Nitric Oxide in Disease Mechanisms, on Amazon since 6/2/12013
http://www.amazon.com/dp/B00DINFFYC
2015 e-Book on Amazon.com
- Metabolic Genomics and Pharmaceutics, on Amazon since 7/21/2015
http://www.amazon.com/dp/B012BB0ZF0
- Cancer Biology & Genomics for Disease Diagnosis, on Amazon since 8/11/2015
http://www.amazon.com/dp/B013RVYR2K
- Genomics Orientations for Personalized Medicine, on Amazon since 11/23/2015
http://www.amazon.com/dp/B018DHBUO6
- Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics, on Amazon.com since 12/27/2015
http://www.amazon.com/dp/B019VH97LU
- Cardiovascular, Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation, on Amazon since 11/30/2015
http://www.amazon.com/dp/B018Q5MCN8
- Cardiovascular Diseases, Volume Three: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics, on Amazon since 11/29/2015
http://www.amazon.com/dp/B018PNHJ84
- Cardiovascular Diseases, Volume Four: Regenerative and Translational Medicine: The Therapeutics Promise for Cardiovascular Diseases, on Amazon since 12/26/2015
http://www.amazon.com/dp/B019UM909A
Completed Volumes in PRINTING Process for 2016 publication
Series C: e-Books on Cancer & Oncology
Volume 2: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery
Authors, Curators and Editors:
Larry H Bernstein, MD, FCAP and Stephen J Williams, PhD
2016
Series E: Patient-Centered Medicine
Volume 2: Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders
Author, Curator and Editor: Larry H Bernstein, MD, FCAP
2016
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.